Clinical trials: Rapid Response System
Rheumatoid Arthritis
TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF
This study will assess the onset and maintenance of effect of tocilizumab on relief in patients with active moderate or severe rheumatoid arthritis who have had an inadequate response to DMARDs or anti-TNF.
- Trial name
- NCT00977106
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 22 sites in France
- Volunteers
- 103 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subjects with Chronic Genotype…
- Trial name
- NCT01435226
- Testing
- GS-5885, GS-9451, tegobuvir
- Where
- 51 sites in United States, Germany
- Volunteers
- 170 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)
This study aim to evaluate the non-inferiority of sustained virologic response in peginterferon alfa-2a and weight-based ribavirin for 16 weeks compare with standard treatment duration of 24 weeks in patients who achieved rapid…
- Trial name
- NCT01056172
- Testing
- Peginterferon alfa-2a and Ribavirin
- Where
- 8 sites in South Korea
- Volunteers
- 164 people
- Sponsor
- Pusan National University Yangsan Hospital
Hepatitis C, Chronic
Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients
In this study we intend to treat patients with chronic hepatitis C of genotype 2 or 3 having characteristics associated with poor treatment response for additional 12 or 24 weeks beyond the standard treatment of PEG-IFN alpha-2b…
- Trial name
- OPTEX2/3 (NCT00803309)
- Testing
- pegylated interferon alpha-2b, Ribavirin
- Where
- 49 sites in Germany
- Volunteers
- 99 people
- Sponsor
- HepNet Study House, German Liverfoundation
Sepsis
Assessing the Procalcitonin-guidance and Molecular-guided Diagnosis for Therapy of Severe Infections (the MODIFY Trial)
MODIFY is a randomized, open-labeled, and prospective study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece.
- Trial name
- MODIFY (NCT05909683)
- Testing
- Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results., Standard of Care
- Where
- 15 sites in Greece
- Volunteers
- 190 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Chronic Genotype 1a or 1b HCV Infection
GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects…
- Trial name
- NCT01434498
- Testing
- GS-5885 tablet, GS-9451 tablet, tegobuvir capsule
- Where
- 50 sites in United States, Canada and 1 more
- Volunteers
- 163 people
- Sponsor
- Gilead Sciences
Type 2 Diabetes
Metabolic Response to 3-day Fast Versus Carbohydrate-free Diet in Type 2 Diabetes
The investigators hypothesis is that a carbohydrate-free diet, ingested for 3 days, results in a change in blood glucose that is similar to the change observed after 3 days of fasting.
- Trial name
- CHO-free diet (NCT01469104)
- Testing
- 3 day fast, 3 day CHO-free diet
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Chronic Hepatitis C
The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C
The efficacy of combination antiviral therapy for chronic hepatitis C is influenced by many factors. Important patient-specific factors include, age, gender, race, body weight.
- Trial name
- NCT01464008
- Testing
- Pegylated interferon alfa-2a and ribavirin
- Where
- China
- Volunteers
- 297 people
- Sponsor
- Beijing Ditan Hospital
Hepatitis C
Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4
Genotype 4 is the least-studied hepatitis C virus genotype and was considered a difficult to treat genotype due to the disappointing response of chronic hepatitis C genotype 4 to conventional interferon monotherapy.
- Trial name
- NCT00277862
- Testing
- Pegylated IFN- alpha 2b, Ribavirin
- Where
- 4 sites in Egypt
- Volunteers
- 280 people
- Sponsor
- Ain Shams University
Parkinson's Disease
Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease
The purpose of this study is to determine whether Fipamezole is effective in the treatment of levodopa-induced dyskinesia in advanced Parkinson's disease.
- Trial name
- Fjord (NCT00559871)
- Testing
- fipamezole
- Where
- 36 sites in United States, India
- Volunteers
- 180 people
- Sponsor
- Juvantia Pharma Ltd
Bloodstream Infection
Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures
This study is designed as a prospective, randomized, open-label trial evaluating antimicrobial utilization, clinical outcomes, and healthcare costs among patients with positive blood cultures.
- Trial name
- NCT03744728
- Testing
- Accelerate PhenoTest™ BC kit, Standard of Care
- Where
- United States
- Volunteers
- 774 people
- Sponsor
- Accelerate Diagnostics, Inc.
Hepatitis C, Chronic
Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C
The purpose of this study is to examine the rapid virologic response (RVR) at combination therapy (CT) Week 4 between groups receiving a standard combination peginterferon alfa-2b/viramidine dosing regimen versus a cohort that…
- Trial name
- NCT00305383
- Testing
- Viramidine, Peginterferon alfa-2b
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Bausch Health Americas, Inc.
Congenital Heart Disease
"Critical State" Early Warning Score After CHD Surgery and Rapid Response Team
By establishing a warning scoring tool for the early \"critical state\" after congenital heart disease surgery, the multidisciplinary rapid response team is proactively activated, forming an integrated treatment model of…
- Trial name
- NCT06578312
- Where
- China
- Volunteers
- 4,115 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Early Warning Score, Monitoring
Observational Study Evaluating the viQtor for Early Detection of Clinical Deterioration in Post-ICU Patients on General Wards
Rationale Following ICU discharge, intermittent vital sign monitoring may delay timely recognition of clinical deterioration and lead to unnecessary readmissions.
- Conditions
- Early Warning Score, Monitoring, Telemedicine-Based Education, Readmission
- Trial name
- ViQtor (NCT06815718)
- Where
- Netherlands
- Volunteers
- 180 people
- Sponsor
- Erasmus Medical Center
Type 2 Diabetes
Substitution of First Phase Insulin Response in Patient With Type 2 Diabetes.
The purpose of the project is to shown whether a little dose of a short acting insulin analogue given 3 time daily before the meals compared with placebo could normalise the increase in blood glucose after teh meals in diet…
- Trial name
- NCT00254085
- Testing
- Insulin Aspart
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Status Epilepticus, Coma
Rapid-Response EEG in Children With Suspected Status Epilepticus
Seizures are common in children (~350 per 100,000 patients per year) and require immediate medical attention. If the seizure is prolonged (> 5 minutes) it is called status epilepticus and delayed treatment leads to higher risk in…
- Trial name
- RECS (NCT06564662)
- Testing
- Rapid Response EEG
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Children's Hospital at Montefiore
Systemic AL Amyloidosis
Rapid dFLC Response Predict CHR in AL Amyloidosis
Light chain amyloidosis (AL amyloidosis) is a rare plasma cell dyscrasia characterized by the deposition of insoluble amyloid fibrils in multiple organ systems.
- Trial name
- NCT06627309
- Testing
- Dara IV, Bortezomib (drug), Dexamethasone
- Where
- 8 sites in China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Type 1 Diabetes
Post-exercise Insulin Reductions in Type 1 Diabetes
The investigators hypothesise that reducing rapid-acting insulin dose after exercise will help prevent Type 1 diabetes individuals experiencing hypoglycaemia.
- Trial name
- NCT01531855
- Testing
- Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- Northumbria University
Hepatitis C Virus Infection
14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response
Patients with HCV genotype 2 or 3 infection who have a rapid virological response to treatment are randomised to either 14 or 24 weeks HCV treatment.
- Trial name
- NCT00308048
- Testing
- Pegylated Interferon alfa 2b and ribavirin
- Where
- Norway
- Volunteers
- 435 people
- Sponsor
- Ullevaal University Hospital
Chronic Hepatitis C, Genotype
A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients
The purposes of this study are: 1. To evaluate whether treatment with peginterferon and ribavirin for 24 weeks is sufficient to achieve a sustained virological response (SVR) rate comparable to that observed with the standard…
- Trial name
- NCT00629967
- Testing
- pegylated interferon alpha 2a and ribavirin, Pegylated interferon alfa-2a and ribavirin
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital